All In Biotech

Drug Trial Radar · NCT06461286

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Oct 31, 2024

Primary completion

Oct 2029

Study completion Nov 2029

Sponsor

Lead sponsor
PYC TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.

Conditions

  • OPA1 Gene Mutation
  • Autosomal Dominant Optic Atrophy
  • Hereditary Optic Atrophies
  • Kjer Optic Atrophy

Interventions

  • PYC-001Drug

    Single Group Assignment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, type, severity and relationship of ocular treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (SAEs) in the study eyeTime frame: 24 weeks
  2. Incidence, type, severity and relationship of ocular treatment-emergent adverse events (TEAEs), and treatment-emergent serious adverse events (SAEs) in the study eyeTime frame: 48 weeks
  3. Incidence, type, severity and relationship of ocular TEAEs, and treatment-emergent SAEs in the fellow eyeTime frame: 24 weeks
  4. Incidence, type, severity and relationship of ocular TEAEs, and treatment-emergent SAEs in the fellow eyeTime frame: 48 weeks
  5. Incidence, type, severity and relationship of non-ocular TEAEs, and treatment-emergent SAEsTime frame: 24 weeks
  6. Incidence, type, severity and relationship of non-ocular TEAEs, and treatment-emergent SAEsTime frame: 48 weeks
  7. Change from baseline for vital signs measurements (heart rate [HR], systolic and diastolic blood pressure [BP], tympanic temperature, respiratory rate [RR])Time frame: 48 weeks
  8. Change from baseline for 12-lead electrocardiogram (ECG) parametersTime frame: 48 weeks
  9. Change from baseline for clinical laboratory results - hematologyTime frame: 48 weeks
  10. Change from baseline for clinical laboratory results - clinical chemistryTime frame: 48 weeks
  11. Change from baseline for clinical laboratory results - coagulationTime frame: 48 weeks
  12. Change from baseline for clinical laboratory results - urinalysisTime frame: 48 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Save Sight Institute - Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Center for Eye Research Australia (CERA)

    East Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.